Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM | Managing infectious complications of CAR-T therapy

Nirali Shah • 15 Oct 2021
COSTEM
General CAR-T

Nirali Shah, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, talks on the management of the infectious complications of chimeric antigen receptor T-cell (CAR-T) therapies targeting different antigens, commenting on implications for clinical practice. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Nirali Shah

1:31
Next steps for improving dual CARs
Nirali Shah • 15 Oct 2021
1:23
The future role of CAR-T in pediatric ALL
Nirali Shah • 15 Oct 2021
3:42
Prior blinatumomab use impacts CD19-CAR T-cell therapy response rates in R/R ALL
Nirali Shah • 25 Nov 2020
1:21
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Nirali Shah • 9 Dec 2017

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals